TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01316614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNA with and without a stylet
Description: If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
Study: NCT04171323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 40 computerized sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 40 computerized sessions.
Study: NCT03105011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EpxDiabetes software
Description: Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
Study: NCT00076570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study: NCT04539275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Masked Saline Placebo
Description: 0.9% saline solution will be used as the Masked Saline Placebo
Study: NCT02957552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
Study: NCT02669849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01687439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 7.5mg/m2, D1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25-30mg/m2, D1,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, D1-3
Study: NCT04171323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 40 computerized sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Stimulation
Description: Participants will be completing a total of 40 computerized cognitive stimulation sessions.
Study: NCT02535429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Study: NCT00875498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active iTBS
Description: Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham iTBS
Description: iTBS placebo (placebo coil)
Study: NCT02187159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet (matching DS5565) for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (matching DS5565) for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (matching DS5565) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration
Study: NCT00899782

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: correlative studies
Study: NCT02662452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 single dose
Description: single ascending doses, oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: single doses, oral suspension, matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 multiple doses
Description: multiple ascending doses, daily for 14 days, oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple doses
Description: multiple doses, daily for 14 days, oral suspension, matching placebo
Study: NCT02601118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro Expression Training Tool
Description: The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
Study: NCT04285203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video Intervention
Description: Educational videos
Study: NCT03711344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
Study: NCT02699723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02423278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Gastrectomy Plus D2 Lymphadenectomy
Description: This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1\&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Gastrectomy Plus D4 Lymphadenectomy
Description: This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1\&2 LNs) and para-aortic lymph nodes must be removed during the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1+Oxaliplatin
Description: A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1+Oxaliplatin
Description: A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
Study: NCT01514253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose 25%
Description: 1 ml glucose 25%, once

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Materna RTF Stage 1
Description: 1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for Injection
Description: 1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
Study: NCT01831947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study: NCT01687439

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT04596319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AP-PA02
Description: Bacteriophage administered via inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo administered via inhalation
Study: NCT01248416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor and Growth Hormone
Study: NCT03183908

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD®
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® High-Dose
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Study: NCT01688713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
Study: NCT03890575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway stent implantation
Description: The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
Study: NCT01060462

Intervention type: DRUG
Intervention: Pts. w/ neutropenic fever associated w/ hematologic malignancy
Description: Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
Study: NCT00861081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management
Description: Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Materials
Description: Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
Study: NCT03799861

Intervention type: OTHER
Intervention: Epoch 2: HBB with NeoBeat
Description: At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.

Intervention type: OTHER
Intervention: Epoch 3: HR-guided HBB
Description: At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
Study: NCT00794144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Nasal Spray 0.6%
Description: one spray in each nostril twice daily for 2 weeks
Study: NCT02652793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted atazanavir
Description: Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 300 mg once dailly
Study: NCT04642989

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: All movements of facial effleurage except applying pressure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: All movements of facial effleurage except applying pressure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: All movements of facial effleurage except applying pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Effleurage
Description: Facial massage to remove any lymphatic blockages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Effleurage
Description: Facial massage to remove any lymphatic blockages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Effleurage
Description: Facial massage to remove any lymphatic blockages

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Appropriate standard-of-care antibiotics as determined by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Appropriate standard-of-care antibiotics as determined by the physician.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotics
Description: Appropriate standard-of-care antibiotics as determined by the physician.
Study: NCT00794144

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine Hydrochloride Nasal Spray Vehicle
Description: one spray in each nostril twice daily for 2 weeks
Study: NCT02643303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Study: NCT01004055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera™ Antimicrobial Wound Dressing
Description: Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTICOAT™ Antimicrobial Barrier Dressing
Description: Dressing changes every 2-3 days, more frequently if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Ag Silver Foam Dressing
Description: Dressing changes every 2-3 days, more frequently if needed
Study: NCT03069703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
Study: NCT03845894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with adjuvants
Description: Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
Study: NCT01490411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v1-FV
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v1-FV
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v1-FV
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v1-FV
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
Study: NCT00193635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral drug administration
Study: NCT02537496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation - Sham
Description: Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
Study: NCT01458587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid PDT (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle PDT (VEH)
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light